DYN

Over the past six months, Dyne Therapeutics' stock has experienced several notable events. In September 2026, shares dropped approximately 37% over 30 days, primarily due to Novartis reporting a Phase 3 failure for its DM1 drug, which impacted the broader muscle-disease sector and led to some analyst price-target cuts, though most maintained bullish ratings. Prior to this, in August 2026, the stock had rallied, reaching a 52-week high near $27.30. In July 2026, the company reported its second-quarter financial results, announced the U.S. FDA cleared its Investigational New Drug Application for DYNE-302 in FSHD, and priced an upsized $375 million public offering of common stock. In June 2026, shares rose following an amendment to a debt facility. In October 2026, Dyne reported additional one-year clinical data from the Phase 1/2 ACHIEVE trial for Z-basivarsen, demonstrating sustained functional improvements in DM1 patients. Additionally, the FDA accepted a Biologics License Application for z-rostudirsen with Priority Review, setting a PDUFA target action date of January 21, 2027, with new cardiopulmonary data from the DELIVER trial reinforcing the potential of the FORCE platform.